Treatment with Folfirinox yielded antitumor responses in 75%-85% of patients with advanced colorectal adenocarcinoma52,53, and Folfox (a combination of FUra, FA, and l-OHP) together with the anti EGFR monoclonal antibody panitumumab produced responses in approximately 70% of Ras-WT patients of whom about 35% had response depth of ≥ 71% tumor reduction54. Here, EGFR is linked to neoplasm.